Brickell Biotech — Technical Presentation (October 2021)
18 slides from Brickell Biotech's technical presentation, Oct 7, 2021
Slide 1: Sofpironium Bromide U.S. Phase 3 Pivotal Program Topline Results
© BrickellBio NASDAC: BBI Sofpironium Bromide U.S. Phase 3 Pivotal Program Topline Results r | Making Fresh Tracks® in Medicine October 7, 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements + This presentation contains forward-looking statements that involve substantial risk and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation other than statements of
Slide 3: Highlights from Today's Announcement
Highlights from Today's Announcement Brickell announces positive topline results from two U.S. Phase 3 pivotal clinical studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients* PE ORCTIOUERTIEYE All primary and secondary endpoints were met and achieved statistical signific
Slide 4: U.S. Phase 3 Pivotal Program Overview (Cardigan I & Cardigan II)
U.S. Phase 3 Pivotal Program Overview (Cardigan | & Cardigan II) STUDY TITLE STUDY DESIGN CO-PRIMARY EFFICACY ENDPOINTS AGREED WITH FDA STUDY POWER CALCULATIONS Multicenter, randomized, double-blinded, vehicle-controlled studies to evaluate the safety and efficacy of topically applied sofpironium br
Slide 5: U.S. Phase 3 Pivotal Program: Subject Disposition
U.S. Phase 3 Pivotal Program: Subject Disposition Overall, 89% of subjects receiving sofpironium bromide (SB) gel, 15% completed 6 weeks of treatment in the Phase 3 pivotal program CARDIGAN | CARDIGAN II Vehicle Vehicle Total SB Gel, 15% (Placebo Gel) Total SB Gel, 15% (Placebo Gel) (n = 173)? (n =
Slide 6: Co-Primary Efficacy Endpoint: Point Improvement in HDSM-Ax-7
Co-Primary Efficacy Endpoint: 22 Point Improvement in HDSM-Ax-7 Sofpironium bromide (SB) gel, 15% demonstrated statistically significant HDSM-Ax-7 responses from baseline to EOT CARDIGAN | CARDIGAN II 22 point improvement in HDSM-Ax-7 22 point improvement in HDSM-Ax-7 from baseline to EOT' from base
Slide 7: Co-Primary Efficacy Endpoint: Change in GSP
Co-Primary Efficacy Endpoint: Change in GSP Sofpironium bromide (SB) gel, 15% demonstrated statistically significant responses compared to vehicle for change in GSP from baseline to EOT CARDIGAN | CARDIGAN II GSP change from baseline to EOT' GSP change from baseline to EOT' Vehicle SB 15% Vehicle SB
Slide 8: Secondary Efficacy Endpoint: Point Improvement in HDSM-Ax-7
Secondary Efficacy Endpoint: 21 Point Improvement in HDSM-Ax-7 Sofpironium bromide (SB) gel, 15% demonstrated statistically significant HDSM-Ax-7 responses from baseline to EOT CARDIGAN | CARDIGAN II HDSM-Ax-7 reduction (21 point improvement) HDSM-Ax-7 reduction (21 point improvement) from baseline
Slide 9: Secondary Efficacy Endpoint: Combined HDSM-Ax-7 & GSP Analysis
Secondary Efficacy Endpoint: Combined HDSM-Ax-7 & GSP Analysis Sofpironium bromide (SB) gel, 15% demonstrated statistically significant responses in a combined HDSM-Ax-7 (22 point improvement) and GSP (270% reduction) analysis from baseline to EOT CARDIGAN | CARDIGAN II HDSM-Ax-7 (22 point improveme
Slide 10: Secondary Efficacy Endpoint: Combined HDSM-Ax-7 & GSP Analysis
Secondary Efficacy Endpoint: Combined HDSM-Ax-7 & GSP Analysis Sofpironium bromide (SB) gel, 15% demonstrated statistically significant responses in a combined HDSM-Ax-7 (21 point improvement) and GSP (250% reduction) analysis from baseline to EOT CARDIGAN | CARDIGAN II HDSM-Ax-7 (21 point improveme
Slide 11: U.S. Phase 3 Pivotal Program: Safety Summary
U.S. Phase 3 Pivotal Program: Safety Summary Majority of treatment-emergent adverse events (TEAEs) were mild or moderate in severity and transient in nature CARDIGAN | CARDIGAN II SB Gel, 15% (Piacabs Geb SB Gel, 15% (Pincabe Geb (n = 173) (n = 176) (n = 180) (n= 171) Any TEAE, n (%) 62 (35.8%) 23 (
Slide 12: Incidence of Treatment-Emergent Adverse Events (≥2% of Subjects)
Incidence of Treatment-Emergent Adverse Events (22% of Subjects) Sofpironium bromide (SB) gel, 15% was observed to be generally well tolerated and adverse events were predominantly mild or moderate in severity CARDIGAN | CARDIGAN II Vehicle Vehicle SB Gel, 15% (Placebo Gel) SB Gel, 15% (Placebo Gel)
Slide 13: U.S. Phase 3 Pivotal Program: Conclusions
U.S. Phase 3 Pivotal Program: Conclusions Cardigan | and Cardigan II results support submission of an NDA to the FDA for sofpironium bromide gel, 15% + Sofpironium bromide gel, 15% resulted in a statistically significant greater proportion of subjects achieving at least a 2-point improvement in HDSM
Slide 14: © BrickellBio
© BrickellBio
Slide 15: Brickell Biotech, Inc.
Brickell Biotech, Inc. (NASDAQ: BBI) Striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debili ting diseases Potential Best-in-Class Cutting-edge Experienced Hyperhidrosis Product Autoimmun
Slide 16: Pipeline of NCEs with Multiple Near-Term Value Inflection Points
Pipeline of NCEs with Multiple Near-Term Value Inflection Points Program Indication(s) Discovery Preclinical Phase | Phase II Phase Ill Approved Next Milestone Primary Axillary Mid-2022 Sofpironium Bromide Hyperhidrosis Retrometabolic Anticholinergic Commercialized in Japan: ECCLOCK® Gel 5% ) Primar
Slide 17: Key Upcoming Milestones for BBI
Key Upcoming Milestones for BBI Sofpironium HEE Bromide U.S. NDA submission for primary axillary hyperhidrosis C) er BBI-02, BBI-03, and Next Generation DYRK1A Inhibitors Initiate Phase 1 clinical Phase 1 topline results study for BBI-O2 for BBI-02 BBI-03 - Formulation development Next Generation -
Slide 18: Thank You!
©& BrickellBio NASDAQ: BBI Thank You! Contact: [email protected] r | Making Fresh Tracks® in Medicine October 7, 2021
Brickell Biotech — Technical Presentation (October 2021) on 6ix